Purpose: The aim of this study was to evaluate 99m Tc-ethylenedicysteine-glucosamine (EC-DG) 
INTRODUCTION
Radionuclide imaging modalities (positron emission tomography [PET] and single photon emission computed tomography [SPECT] ) are used to map the location and concentration of radionuclide-labeled compounds. [1] [2] [3] Among all radioisotopes, 99m Tc has been preferred to label radiopharmaceuticals because of favorable low energy (140 Kev versus 511 Kev for 18 F) and inexpensive isotope cost ($0.21/mCi versus $30-$50/ mCi for 18 F). Several 99m Tc-labeling techniques have been reported, such as N 4 (e.g., DOTA), N 3 S (e.g., MAG-3), N 2 S 2 (e.g., ECD), NS 3, S 4 (e.g., sulfur colloid), diethylenetriamine penta-acetic acid (DTPA), and hydrazinenicotinamide (HYNIC). [4] [5] [6] [7] [8] [9] [10] Among these chelators, the HYNIC technique requires two additional chemicals (tricine, triphenylphosphine) in order to form a 99m Tc complex, thus making it inconvenient and costly. The nitrogen and sulfur combination has been shown to be a stable chelator for 99m Tc. Bis-aminoethanethiol tetradentate ligands, also called diaminodithiol compounds, are known to form very stable Tc(V)O-complexes on the basis of efficient binding of the oxotechnetium group to two thiolsulfur and two amine nitrogen atoms. 99m Tc-L,L-ethylenedicysteine ( 99m Tc-EC) is the most recent and successful example of N 2 S 2 chelates. EC can be labeled with 99m Tc easily and efficiently with high radiochemical purity and stability. 11, 12 We have previously reported a series of 99m Tc-EC-agent conjugates for functional imaging in oncology. [13] [14] [15] [16] [17] [18] [19] [20] In addition, EC can also be labeled with 68 Ga for PET imaging and 188 Re (a beta and gamma emitter) for internal radionuclide therapy. 21-23 99m Tc, 68 Ga, and 188 Re are generator-produced isotopes that are accessible and affordable.
There is a structural similarity between FDG and glucosamine (structure shown in Fig. 1 ). At position 2 of the sugar, FDG and glucosamine have the fluorine and amino group, respectively. Similar to FDG, the cellular uptake of glucosamine is by a glucose transporter process. 19 However, its regulatory products of glucosamine-6-phosphate mediate insulin activation, downstream signaling, and translocation, which upregulate mRNA expression and tumor growth. 24, 25 For instance, Sp-1 is one of the known transcription factors whose activity may be post-translationally triggered by glucosamine. [26] [27] [28] Sp-1 binding sites are possible to be present in the promoters of potent angiogenic growth factors, such as VEGF and IL-8, and regulate oncogenic factors with cell-cycle factors at the basal level of transcription or repression. Therefore, radiolabeled glucosamine may be able to noninvasively assess cell nuclei activity and characterize tumor growth. We have then developed 99m Tc-EC-glucosamine ( 99m Tc-EC-DG) for tumor tissue-specific targeted imaging.
Results from our animal studies showed that the binding of 99m Tc-EC-DG in tumors can be imaged. 19 Our 99m Tc-EC-DG instant kit has obtained IRB (ID 01-415) and IND (#63,698) approval from the University of Texas M.D. Anderson Cancer Center and the Food and Drug Administration (FDA). A phase I trial, using 99m Tc-EC-DG to image tumors in patients with head, neck, and lung cancer, is in progress. In this paper, we evaluated the role of 99m Tc-EC-DG in chemotherapeutic response assessment in animal models. Paclitaxel (Sigma Chemical Co., St. Louis, MO) and cisplatin were selected in the animal studies because they have demonstrated significant antitumor effect against mammary tumors. [29] [30] [31] [32] [33] [34] [35] [36] Paclitaxel increases microtubule stability by preventing tubulin depolymerization, which results in tubulin bundling. 31, 32 Paclitaxel also mediates a direct antiangiogenic effect against several cell lines. 33, 34 Cisplatin has been involved in cell-cycle arrest in various types of tumor cells. 35, 36 The correlation of biologic markers with the tumor uptake of 99m Tc-EC-DG was studied.
MATERIALS AND METHODS

Synthesis of Ethylenedicysteine (EC)
Cysteine-HCl (41.52 g) was dissolved in water (106 mL). To this solution, formaldehyde was added (26.1 mL), and the reaction mixture was stirred overnight at room temperature. Pyridine (26.6 mL) was then added and the precipitate formed. The crystals were separated and washed with ethanol (54 mL) for 25 minutes at room temperature, then filtered with a Buchner funnel. The crystals were triturated with petroleum ether (150 mL), again filtered, and then lyophilized for 3 days. The precursor, L-thiazolidine-4-carboxylic acid (m.p. 195°C, reported 196°C-197°C), was used for the synthesis of EC. The precursor (22 g ) was dissolved in liquid ammonia (200 mL) and refluxed. Sodium metal was added until a persistent blue color appeared. Ammonium chloride was added to the blue solution, and then the solvents were evaporated to dryness. The residue was dissolved in water (200 mL), and the pH was adjusted to 2. A precipitate formed and was filtered and washed with water (500 mL). The solid was dried in a calcium chloride dessicator. EC was then prepared (m.p. 243°C-246°C, reported 251°C-253°C).
445
Synthesis of 99m Tc-ethylenedicysteineGlucosamine ( 99m Tc-EC-DG) EC was conjugated to glucosamine according to an established method, as described in our previous literature. 19 Briefly, sodium hydroxide (1N, 1 mL) was added to a stirred solution of EC (110 mg, 0.41 mmol) in water (5 mL). To this colorless solution, sulfo-N-hydroxysuccinimide (Pierce Chemical Co., Radford, IL) (241.6 mg, 1.12 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide-HCl (Aldrich Chemical Co., Milwaukee, WI) (218.8 mg, 1.15 mmol) were added. D-Glucosamine hydrochloride salt (Sigma Chemical Co., St. Louis, MO) (356.8 mg, 1.65 mmol) was then added. The mixture was then stirred at room temperature for 24 hours. The mixture was then filtered through a 0.45 micron filter, and the pH of the solution was adjusted to 6.4-7.0. To remove the unreacted starting materials, the mixture was dialyzed for 48 hours using Spectra/POR molecular porous membrane, with the cut-off at 500 (Spectrum Medical Industries Inc., Houston, TX). After dialysis, the product was freeze-dried dried using a lyophilizer (Labconco, Kansas City, MO). The product weighed 291 mg (yield 60% The radiosynthesis of 99m Tc-EC-DG was achieved by adding 99m Tc-pertechnetate (40-50 mCi) into the lyophilized residue of EC-DG (50 mg) and tin (II) chloride (SnCl 2 , 100 g). The complexation of EC-DG with 99m Tc was carried out at a pH of 6.5. Radiochemical purity was determined by TLC (ITLC SG, Gelman Sciences, Ann Arbor, MI) eluted with ammonium acetate (1M in water):methanol (4:1). High-performance liquid chromatography (HPLC), equipped with a NaI detector and UV detector (254 nm), was performed on a gel permeation column (Biosep SEC-S3000, 7.8 ϫ 300 mm, Phenomenex, Torrance, CA) using a flow rate of 1.0 mL/min. The eluant was 0.1% LiBr in phosphate buffered saline (PBS) (10 mM, pH ϭ 7.4). The stability of the 99m Tc-EC-DG kit was tested in serum samples. Briefly, 99m Tc-EC-DG (100 Ci) was incubated in dog serum (200 l) at 37°C at 0. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hours. The serum samples were diluted with 50% methanol in water, and radio-TLC was used to analyze the product.
In Vitro [ 3 H]Thymidine Incorporation and Cell-Cycle Assays
Previous studies have shown that the cellular uptake of 99m Tc-EC-DG was by a glucose-mediated process. 19 99m Tc-EC-DG may share the same pathway as glucose. To demonstrate if EC-DG and glucose are involved in cancer cells' proliferation or growth, thymidine incorporation assays were conducted. 99m Tc-EC-DG is a tumor-seeking agent that can image various tumor types. Thus, we used different cancer cells in various studies. Thymidine incorporation assays were conducted in lung cancer cells. Briefly, human lung tumor cells (A549) were plated at 50,000 cells/well in 1 mL RPMI-1640. Unlabeled EC-DG raw material, FDG, and d-glucose (0.1-1 mg in 20 l/well) (Aldrich Chemical Co., Milwaukee, WI) and saline (control) were added to this 12-well culture plate and incubated in 5% CO 2 /air at 37°C. After 24 hours, each well was washed with sterile PBS, and fresh RPMI-1640 was added to each well. Each well was applied with 0.5 Ci/10 l saline of [ 3 H]thymidine and incubated for 24 hours. Finally, each well was washed with ice-cold PBS and typsinized with 100 L of typsin and incubated for 10 minutes in the incubator. The mixture was filtered through a cell harvester. The filters containing cells were added with the cocktail, and radioactivity was counted. The cellular uptake of [ 3 H]thymidine in the control group was unified to be 100 (baseline).
To determine whether EC-DG is involved in the cell-cycle process, breast cancer cells were used in this study. Briefly, breast cancer cells (20 M, adherent) were cultured in RPMI-1640 in a T75 flask. The cells were washed with PBS twice, and serum-free media was added. Hoechst 33342 (5 L) per 1 mL of RPMI-1640 (stock solution: 1 mg/ml) was added. The media was aspirated and washed with PBS. The cells were trypsinized, collected, and sorted. The sorted cells were plated to a 12-well plate (50,000 cells/well), and 4 Ci of 99m Tc-EC-DG, 99m Tc-EC, or 18 F-FDG (CTI Co., Houston, TX) were added. The specific activity of 99m Tc-EC-DG and 99m Tc-EC was 25 mg/5 mL/mCi. After incubation for 2 hours, cells were washed with ice-cold PBS and trypsinized. Then, cells were collected and the radioactivity was measured by a gamma counter.
Effect of Transchelators on the Cellular Uptake of the 99m Tc-EC-DG Kit
To determine the effect of transchelators on the cellular uptake of the 99m Tc-EC-DG kit, 99m Tcpertechnetate was added into a homemade kit containing the lyophilized residue of EC-DG (5 mg) and tin (II) chloride (SnCl 2 , 100 g in 0.1 mL water) and gluconate or glucarate (Aldrich Chemical Co., Milwaukee, WI) (10%-40% w/w of EC-DG). The complexation of EC-DG with 99m Tc was carried out at a pH of 6.5. Radiochemical purity was determined by ITLC eluted with ammonium acetate (1 M in water):methanol (4:1). Breast cancer cell line (13762) was used in these assays. The cell line was obtained from American Type Culture Collection (Rockville, MD). The cells were plated to a 12-well tissueculture plate that contained 50,000 cells/well. The cells were incubated with sodium gluconate or sodium glucarate (10-40 g/well, with a concentration of 0.5-2mg/mL, 10%-40% w/w per well) for 30 minutes, followed by adding 4 Ci (0.148 MBq) of 99m Tc-EC-DG (0.1 mg/well, with a concentration of 5 mg/mL) to each well, and the cells were incubated at 37°C for 2 hours. Control groups were 99m Tc-gluconate and 99m Tc-glucarate (0.1 mg/well, with a concentration of 5 mg/mL). After incubation, the cells were washed with ice-cold PBS twice and trypsinized with 0.5 mL of trypsin solution. Then, the cells were collected, and the radioactivity was measured by a gamma counter (Packard Instruments, Downers Grove, IL). Data were expressed in mean Ϯ standard deviation (SD) percent of uptake (4 Ci ϭ 100%) of three measurements.
Dosimetry of 99m Tc-EC-DG Kit in TumorBearing Mice
The animals were housed in The University of Texas M.D. Anderson Cancer Center facility. All protocols involving animals were approved by the M.D. Anderson Animal Use and Care Committee. Athymic nude mice (20-25 g) were inoculated subcutaneously with 0.1 mL of human lung tumor cells (A549, 10 6 cells/mouse) into the hind legs, using 25-gauge needles. Biodistribution studies were performed 17-21 days after implantation, when tumors reached approximately 0.6 cm in diameter.
Each animal was injected intravenously (i.v.) with 1-2 Ci (per mouse) of 99m Tc-EC-DG containing 20% gluconate (n ϭ 3 mice/time point). Gluconate concentration was obtained from the in vitro studes, as described in the above text. The physical amounts of EC-DG, gluconate, and SnCl 2 used were 5 mg, 1 mg, and 0.1 mg, respectively. The radioactivity concentration and i.v. injection volume were 0.2 mCi/10 mL and 0.1 mL/mouse. At 0.5-4 hours following the administration of 99m Tc-EC-DG, the rodents were sacrificed.
Radioactivity in each sample tissue was calculated as the percentage of the injected dose per gram of tissue wet weight (%ID/g). 19 Dosimetric calculations were performed using time-activity curves, which were generated for each organ. Analytic integration of the curves was used to determine the area under the curve (AUC), which was then divided by injected dose to yield the residence time of each organ. Residence times were then used to calculate the target organ-absorbed radiation doses based on the MIRD methodology for the normal adult male, using the MIRDose 3.1 software package (Oak Ridge Institute for Science and Education, Knoxville, Tennessee). 37 
Autoradiographic Studies
99m Tc-EC-DG containing 20% gluconate was used in this study. The physical amounts of EC-DG, gluconate, and SnCl 2 used in autoradiographic studies were 5 mg, 1 mg, and 0.1 mg, respectively. The radioactivity concentration and i.v. injection volume were 1 mCi/mL and 0.1 mL/mouse. Following an i.v. injection of 100 Ci of 99m Tc-EC-DG and 18 F-FDG, uterine tumor-bearing nude mice were killed at 1 hour, and the body was fixed in carboxymethyl cellulose (3%). The frozen body was mounted onto a cryostat (LKB 2250 cryomicrotome) and cut into 100-m coronal sections. Each section was thawed and mounted on a slide. The slide was then placed in contact with a multipurpose phosphor storage screen (Cyclone Storage Phosphor System, Packard, Meridian, CT) and exposed for 15 hours.
Gamma Scintigraphic Imaging Studies in VX-2 Tumor-Bearing Rabbits
New Zealand White Rabbits (2.5-3 kg) were inoculated with VX-2 tumor mass (rabbit-driven squamaceous mammary tumor) using 18-gauge needles. The rabbits were administered i.v. 99m Tc-EC-DG (containing 20% gluconate) or 99m Tc-EC (control). The physical amounts of 
mCi/mL and 1 mL/rabbit. Rabbits were anesthetized using isoflurane and positioned supine, and scintigraphic images were obtained using a 2020tc Imager gamma camera from Digirad (San Diego, CA). The camera was equipped with a low-energy, parallel-hole collimator. The field of view of Digirad is 20 cm ϫ 20 cm, with an edge of 1.3 cm. The intrinsic spatial resolution is 3 mm, and the matrix is 64 ϫ 64. With a low-energy, high-resolution collimator installed (as required with 99m Tc), the system is designed for a planar sensitivity of at least 125 counts/minute (cpm)/Ci and a spatial resolution of 7.6 mm.
Therapeutic Response Assessment
On day 14 postinoculation, mammary tumorbearing rats (150-175 g, n ϭ 5 rats/agent) were administered a single i.v. injection of Taxol (20 mg/kg) or saline. On day 23 postinoculation (9 days post-therapy), tumor-bearing rats were imaged with a 99m Tc-EC-DG kit (300 Ci/rat, i.v.) at 0.5-2 hours after administration. The physical amounts of EC-DG, gluconate, and SnCl 2 used in imaging studies were 5 mg, 1 mg, and 0.1 mg, respectively. The radioactivity concentration and injection volume were 1 mCi/mL and 0.3 mL/rat. After the imaging procedures were completed, the rats were killed and tumor lesions were removed for immunohistochemical staining, 17 in order to assess the antiangiogenic effect of the therapy. A similar study was conducted using cisplatin (CDDP). Mammary tumor-bearing rats were treated with CDDP (4 and 8 mg/kg, i.p.) on day 14. In these rats, gamma images were acquired on days 14 (baseline), 18, and 39 postinoculation. Computer-outlined regions of interest (ROI) (counts per pixel) of the tumor lesion site and the symmetric normal muscle site were used to determine tumor-to-background count/density ratios. The ratios were used to compare dynamic tumor uptake pre-and post-treatment. To assess locoregional radioactivity, a small handheld gamma camera (eZ-SCOPE, Anzai Medical Co., Ltd., Tokyo, Japan) was also used with a low-energy, parallel-hole collimator (high-sensitive type). The field of view for eZ-SCOPE is 32 mm ϫ 32 mm with 16 ϫ 16 pixels, of which intrinsic spatial resolution is 2 mm and sensitivity is 770,000 cps/MBq.
The effects of Taxol and CDDP on cell-cycle distribution and percentage of apoptotic cells was determined by flow cytometric and immunofluorescence assays (fluorescence activated cell sorter; FACS), using known procedures. 38 
RESULTS
In Vitro [ 3 H]Thymidine Incorporation and Cell-Cycle Assays
[ 3 H]Thymidine incorporation assay suggest that EC-DG and glucose incorporated into cell nuclei activity (Fig. 2) . FDG showed a decreased uptake in a dose-dependent manner, suggesting either the result of cytotoxic effect or less involvement in cell nuclei activity. Cell sorter assays indicated that 99m Tc-EC-DG was involved in cell-cycle proliferation, whereas 18 F-FDG had little or no involvement (Fig. 3) .
Effect of Transchelators on Cellular Uptake of 99m Tc-EC-DG Kit
To achieve a high radiochemical yield, transchelators are commonly used in labeling conditions. Gluconate and glucarate, auxilliary chelating agents, were introduced to 99m Tc-EC-DG, and their effect on the cellular uptake of 99m Tc-EC-DG was evaluated. The transchelation preparation of the 99m Tc-EC-DG kit using 10%-40% (w/w) gluconate or glucarate was attempted. The radiochemical yield was Ͼ96%. Adding transchelators, such as gluconate and glucarate, did not alter the cellular uptake of 99m Tc-EC-DG (Fig. 4) . The findings indicate that gluconate and glucarate play a complimentary role in the stability of 99m Tc-EC-DG during the formulation of the 99m Tc-EC-DG kit.
Dosimetry of 99m Tc-EC-DG Kit in Tumorbearing Mice
The estimated radiation-absorbed dose is shown in Table 1 . If the subject does not involve other radiation exposure, whole body, kidneys, liver, and the effective dose equivalent for the proposed single dose at 20-25 mCi (a common dose used in nuclear medicine practice) falls below the limits for 3 rem annual and 5 rem total-dose equivalent, and other organs of single dose at 5 rem annual and total-dose equivalent at 15 rem. The physical amount of EC-DG and radioactive concentration is 50 mg and 50 mCi/mL. The specific activity is 0.6 mCi/mol.
Autoradiographic and Gamma Scintigraphic Imaging Studies
Compared to 18 F-FDG autoradiogram, less brain and heart uptake was observed in 99m Tc-EC-DG by visualization. Tumor uptake was well visualized by 99m Tc-EC-DG (Fig. 5) . D-glucosamine (DG), an antirheumatic drug exhibiting a natural tropism for cartilaginous tissues, has been labeled with 14 C-DG for pharmacokinetic studies. 39 Biodistribution and autoradiogram of 14 C-DG indicated poor brain and heart uptake, which showed a similar pattern to our autoradiographic findings. In gamma scintigraphic imaging studies, compared to 99m Tc-EC (control), a tumor could be visualized by 99m Tc-EC-DG in VX-2 tumorbearing rabbits. For comparative analysis, tumorto-muscle (counts/pixel, right leg) ratios were determined. Tumor-muscle ratios for 99m Tc-EC and 99m Tc-EC-DG were 1.13 and 3.20 (Fig. 6 ).
Therapeutic Response Assessment
99m Tc-EC-DG is capable of measuring tumorvolume changes after Taxol and cisplatin treatment in rodents (Figs. 7-10 ). An angiogenesis main regulator, such as bFGF expression in solid tumors, was decreased after Taxol treatment, compared to untreated rats (Fig. 8) . Cell-cycle analysis indicated specific cell cycle G1 and G2 phase changes and increased apoptosis postTaxol and cisplatin treatment (Fig. 9) . The cells were arrested at the G2 phase after Taxol and cisplatin treatment. A complete remission was observed at 8 mg/kg, whereas a partial remission was noted at 4 mg/kg of CDDP (Fig. 10) . ROI analysis showed a marked decrease in tumor-tomuscle ratios (3.16-1.02) post-CDDP treatment in the complete remission group; however, increased tumor-to-muscle ratios (3.27-4.36) were observed in the partial remission group (tumor regrow) on day 39 postinoculation. Immunohistochemistry revealed more viable tumor cells at low-dose than that at high-dose (8 mg/kg) CDDP treatment (Fig. 11) . The findings indicated the feasibility of image-guided therapy using 99m Tc-EC-DG. Serial imagings are also possible with a Figure 6 . Each rabbit was scanned twice (upper and lower) due to the limitation of the camera. Rabbit imaging. Planar scintigraphic images of VX-2 tumor-bearing male rabbits after an administration of 99m Tc-EC and 99m Tc-EC-DG (1 mCi, i.v.) showed that the tumor could be well-visualized at 1 hour postinjection. (T, tumor, A, site for anesthesia administration). Tumor/muscle ratios for 99m Tc-EC and 99m Tc-EC-DG were 1.13 and 3.20.
6-hour half-life of 99m Tc to generate increasing retention of 99m Tc-EC-DG in tumors.
DISCUSSION
Assessment of the effectiveness of cancer therapy (e.g., volumetric and morphological changes) is measured by CT and MRI. In addition to these imaging modalities, the treatment endpoints rely almost exclusively on the analysis of biopsies by molecular and histopathological methods. These methods provide a microscopic picture of the general heterogeneous process. Therefore, to assess clinical endpoints adequately, a cell nuclei activity marker is needed that would allow for the precise, spacio-temporal measurement of tumor targets on a whole-body image upon the administration of a functional agent. These mechanismbased agents provide image-guided therapy, which may discontinue ineffective treatment in the earlier phase and switch to a more efficient treatment that would be beneficial to patients early in the course of treatment. PET and SPECT use radiotracers to image, map, and measure target-site activities (e.g., angiogenesis, metabolism, apoptosis, and proliferation), and they are considered as molecular imaging modalities. Reliable molecular imaging assays that assess:
(1) cellular targets at low cost, (2) treatment response more rapidly, (3) differential diagnosis, (4) the prediction of therapeutic response, and (5) better dosimetry for internal radiotherapy would be very valuable. Though FDG-PET imaging demonstrates the increased glucose consumption of malignant cells, problems with specificity for cell proliferation have led to the development of new PET tracers. 18 F-FDG could assess metabolic activity, but it could not adequately assess cell nuclei activity. Thus, 18 F-FDG imaging could not differentiate infection/inflammation from tumor recurrence. Serial imagings have been proposed to measure a greater retention of FDG in tumors, but they are practically limited with a 2-hour half-life of 18 F. To develop a tumorspecific agent, it is necessary to assess cell nuclei activity. An assessment of cell nuclei activity provides potential applications in differential diagnosis and the prediction of early treatment response. Previously, we have reported that the tumor uptake of 99m Tc-EC-DG is by a glucose-mediated process. 19 Autoradiograms and planar imaging studies showed that there was less brain uptake in 99m Tc-EC-DG than in 18 F-FDG. Poor brain uptake of radiolabeled glucosamine was also reported by others. 39 There are at least five glucose transporters. Glucose transporters 1 and 3 are localized in brain tissue. 99m Tc-EC-DG may use a different glucose transporter to enter cells.
After completeing several experiments, which are illustrated in this paper, there appears to be a strong correlation that EC-DG is involved in cancer cells' synthesis or growth. This conclusion is based on the fact that EC-DG and glucose show similar uptake patterns in the thymidine incorporation assay and that EC-DG is directly involved in the cell-cycle processes (Figs. 2 and 3) . EC-DG and glucose are involved in the proliferation/growth activity of the cells. The reason why FDG may not be involved in the growth activity is because of the fluorine atom in position 2 of the molecule, which cannot interact with cytosolic protein. FDG is not directly involved in the cell-cycle processes (Fig. 3) . The involvement of EC-DG in the whole cell-cycle pathway would allow for continuous post-treatment follow-ups.
Glucosamine and glucose share the same pathway(s). Whereas glucose may only share 4% of Figure 8 . Immunohistochemical staining of tumor sections from mammary tumor-bearing rats treated with a single injection of Taxol (20 mg/kg, i.v.) showed that bFGF expression was decreased, compared to no treatment. A rat in the control group was randomly selected pretreatment, and a rat with similar tumor volume in the control group was selected for Taxol treatment. the hexosamine biosynthetic pathway, glucosamine is possibly sharing approximately 96% of both the glycolytic/TCA and the hexosamine pathways. One reason for this may be that the molecule (EC-DG) has very key position(s)-for example, at positions 2 and 6 for D-Glucosamine and EC, the 2 COO-arms and the 2 dithiols (SH) locations. During synthesis, the molecule changes to a peptide linkage, with two sugar arms with EC linked at position 2 at both sites of the sugars. EC has formed a peptide-bond linkage with 2 dithiols, which can react with glycoproteins and the lumen of the cell membrane, such as O-linked N-acetylglucosamine. [24] [25] [26] [27] It is likely that SH bonds of EC-DG bind to cytosolic and transmembrane enzymes (Beta-N-acetylglu- cosaminidase and O-GlcNAc transferase) or membrane-assocated proteins (O-linked N-acetylglucosamine), which form (EC-DG)S-S(protein) linkages and support the translocation of EC-DG into the cell nucleus, because it is known that glucosamine is phosphorylated at positions 1 and 6 and binds with uridine diphospho-N-acetylglucosamine to form O-linked N-acetylglucosamine at those same positions, which involves nuclear and cytosolic proteins interaction. Recent studies demonstrate a role for O-GlcNAcylation in processes as diverse as transcription in the nucleus and signaling in the cytoplasm, suggesting that OGlcNAc has both protein-and site-specific influences on biochemistry and metabolism throughout the cell. 24, 25 We believe that it is this mechanism that is occurring, which makes EC-DG so unique in its ability to be internalized by the cell.
CONCLUSION
In summary, the EC-DG kit can be labeled with 99m Tc easily and efficiently, with high radiochemical purity and is cost-effective. In vitro cellular uptake and scintigraphic imaging studies demonstrated the pharmacokinetic distribution and feasibility of using 99m Tc-labeled deoxyglucose for the image-guided therapy of cancer. There was a correlation between tumor uptake and molecular tagets (e.g., bFGF, cell cycle) expression. With complex mechanisms expressed in tumor-tissue growth, the technique developed allows for mechanism-specific targeted assessment of cell nuclei activity using 99m Tc-EC-DG.
